SARS-CoV-2 / COVID-19 Pandemic Case Study Resources and Primary Source Reader


SARS-CoV-2 / COVID-19 Pandemic Case Study Resources

and Primary Source Reader

K. Lee Lerner

Contact: and

Creative Commons License (CC BY-ND-NC-ND 4.0)




This is a highly curated timeline and set of  references intended memorialize our evolution of scientific understandings of the virus, the disease, and our early responses to what became the COVID-19 pandemic. Although there are references early in this timeline to nCoV-2019 and/or the novel Wuhan coronavirus outbreak, the virus is now officially named SARS-CoV2 (also styled SARS-CoV-2). The disease associated with the virus is now known as COVID-19 (also styled as Covid-19).

In some cases  updates and additional resources are found indented below main entries. Some enties and comments refer to intermediate hypotheses and data later discarded or modified.  

The early calculations of the Ro (R naught) of the SARS-CoV-2  viral outbreak ranged between 1.4 to 2.5. Ro (or R naught) is a measure of transmissibility , the number of people one person who is infected is expected to spread the Ro = β κ D where β equals the transmissibility of an infected person to a susceptible individual; κ equals the average number of contacts over time unit in healthy normal pop and D equals the average duration of infectivity. When the Ro is greater than 1 (Ro > 1) a viral disease will spread. 

People often say "the Ro of the virus is such-and-such, but Ro is really a characteristic of the outbreak A component, β, the transmissibility factor is related specifically to a virus and is a characteristic of the virus (i.e., some are more transmissible than others, etc.). But Ro also depends on the normal number of contacts ( κ ) in a VULNERABLE population. Accordingly, If a highly contagious virus is introduced Into a population that is not vulnerable (e.g., has resistance or immunity due to prior exposure or vaccination) then the Ro would be zero. As this is a novel coronavirus, everyone is vulnerable. Over time, with an accumulating population of people with acquired immunity due to prior exposure, one would expect the Ro to diminish. Conversely, in a cruise ship setting or nursing home where the number of contacts with vulnerable people is higher then one should see an elevated Ro with a novel virus to which no one has resistance or immunity. 

Early in the outbreak, the novel coronavirus quickly showed changes in transmissibility, meaning that either the data was faulty or that evolutionary mechanisms are allowing the novel coronavirus to find ways to become more easily transmissible (hence the Ro's β factor might change as a virus evolves and an epidemic proceeds). 

During the first months of the outbreak the fatality rate ranged between 2 and 3.4 percent. In terms of disease impacts, as I commented in my opening in January, this makes this novel coronavirus much more like the pandemic 1918 flu that killed millions than SARS or MERS. 

But. but.. but.. we now have clinical supportive measures and antivirals that did not exist in 1918 and so this will be an interesting test of the global health response. The lethality rate would normally be expected to be higher in areas without adequate medical infrastructure, etc. Moreover, the lethality rate is usually an overestimate of the actual lethality rate because many cases are not confirmed, and in some areas, go unreported by individuals who are either asymptomatic or have mild case. We won't have a handle on the lethality of SARS-CoV-2 until we do more testing, including serotesting of those who die but who may not have been laboratory confirmed cases.

Even if the lethality drops to 1% that still means SARS-CoV-2 is 10 to 20 times more lethal than the typical seasonal flu. Harvard epidemiologists initially expected 40% to 70 percent of the world's population to become infected. Given the numbers above, the best case scenario for a world of 7.5 billion people is that if only 40 percent become infected at 1% lethality then that 3 billion infected with 30 million dead. At the other extreme at the currently observed 3.4% lethality we would expect 5.25 billion people infected with 178.5 million dead. Those are two very different worlds.

It would be good for the experts to be very wrong, but it is irresponsible to think that any of this is impossible or simply dystopian. Good public health measures — and shared community responsibility — can reduce the chances of either nightmare scenario manifesting.

In creating this reference, I focused on essential articles from peer-reviewed journals but I have also added in some general news and opinion pieces that contained solid science and/or were important to understanding the evolution of the pandemic. In some cases I have included comments taken from contemporaneous facebook posting of the article, reference, or event . 

In general, I have avoided politics, but the timeline and archive should be useful to those wanting to provide context for stories (e.g., what was known and when).

 I have also taken care to include scientific articles that address and debunk the current crop of conspiracy theories related to SARS-Cov-2 and the COVID-19 pandemic. It is my experience, however, that there is no set of facts the conspiratorial minded can't twist, cherry pick, or dismiss in their pursuit of the byzantine.

Some of the reading relates to work for a client who has graciously allowed me to share resources collected for that endeavor. This thread also incorporates many of the articles --and some of my comments — from a thread a thread I started on Facebook for friends and colleagues in January 2020. Alas, the platform does not allow me to transfer comments and so many questions and insights offered by friends and colleagues were lost in the formulation of this thread. Quite a few hat tips to Jay Flynn were also lost and are owed for his suggestions and sharing of articles he posted to his own curated thread. 

Thanks are also due to the many publishers who, very early on, opened their archives to the world to help improve communication among scientists, inform the public, defeat misinformation, and speed us toward the day when COVID-19 will no longer be a threat. 

This is  designed to be an educational reference resource While this is primarily for my own use now and in the future, you are welcome to use or share this thread. Please make any comments related to the articles posted only in the reply thread below each individual article.

This collection is intended for educational use and as a reference for journalists covering the pandemic.  A Creative Commons License (CC By-NC-ND 4.0) is granted with author attribution under the following term: No commercial use is permitted and changes/derivatives are not authorized.

Articles listed are linked to their peer-reviewed source. In some cases where timing is critical, the date listed is the date submitted or a preprint posted rather than the journal publication date. 

If over time links corrupt, full text .pdf copies are available for download at




December 2019



20191230 On the evening of Dec 2019 [Local], an "urgent notice on the treatment of pneumonia of unknown cause" was issued, which was widely distributed on the Internet by the red-headed document of the Medical Administration and Medical Administration of Wuhan Municipal Health Committee. Source: Finance Sina [machine translation]  (See Promed post 20191230 PROMED Undiagnosed pneumonia - China.  Note date and time differences due to places of publication. 











20191231 20191230* PROMED Undiagnosed pneumonia - China. request for Information (RFI)

*Note date and time difference due to origin of publications.

Key items: 

Chinese health officials and agencies confirm outbreaks and says China implements "public opinion control."  

"On [31 Dec 2019], various hospitals in Wuhan held an emergency symposium on the topic of the treatment of patients with pneumonia of unknown cause in some medical institutions…." China health officials say that there is "a mature prevention and treatment system in place, and citizens need not panic."

On [31 Dec 2019], An official report from Hubei Province said: "Following the report of the Provincial Health and Health Commission, since December [2019], Wuhan has continued to monitor influenza and related diseases, and 27 cases of viral pneumonia have been found, all of which were diagnosed with viral pneumonia / pulmonary infection. Of the 27 cases, 7 were critically ill…" 

"The investigation found that most of the cases were operated by South China Seafood City in Jianghan District, Wuhan. The National Health and Health Commission has decided to send an expert group to our province to guide the epidemic disposal on the morning of [31 Dec 2019]. 

At present, related virus typing, isolation treatment, public opinion control, and terminal disinfection are underway."



January 2020



20200101 SCMP - World Health Organisation in touch with Beijing after mystery viral pneumonia  outbreak.

Key Points:  Mere suspicion of something unusual put Hong Kong on alert. "Medical authorities in Hong Kong, which is about four hours from Wuhan by high-speed train, said late on Tuesday they had stepped up border screening and put hospitals in the city on alert. 'The situation in Wuhan is unusual, and we are not sure about the reasons behind the outbreak yet,' Hong Kong’s Secretary for Food and Health Sophia Chan Siu-chee." “Since we are now in the holiday season, and Hong Kong has close transport ties with Wuhan, we must stay alert.” 


20200102 ProMed - Undiagnosed pneumonia - China wildlife sales, market closed, RFI


20200103 PROMED -Undiagnosed pneumonia - China, updates, other country responses, RFI


20200105 Promed - Undiagnosed pneumonia - China  SARS, MERS ruled out, WHO, RFI


20200105 In China the genomic sequence of the suspect novel coronavirus associated with the undiagnosed pneumonia is reported isolated and articulated on 5 January 2020. The researcher, Yong-Zhen Zhang ( responsible — via the Shanghai Public Health Clinical Centre — reported his findings to China's National Health Commission along with a warning that that virus had a sequence close to others "previously found in bats" and a recommendation that "relevant prevention and control measures” be taken in public places. After failing to receive a response, Zhang, via collaborating colleague Edward C. Holmes at University of Sydney, directly submits the sequence to GenBank and posts notice on entry on 20200111, January 11, 2020). Zhang's lab is closed the next day (January 12) for "rectification" by order of the Shanghai Health Commission. Source: South China Morning Post (see 20200228 SMCP article Chinese laboratory that first shared coronavirus genome with world ordered to close for 'rectification', hindering its Covid-19 research



20200106 CDC alert: Pneumonia of unknown cause in China.   CDC issues Level 1 "Watch" notice: US CDC issues three levels of travel notices: Level 1 / Watch -  practice usual precautions; Level 2 / Alert - practice enhanced precautions; and level 3 / Warning - avoid nonessential travel. 

Key Points:

No deaths or human to human transmission reported (e.g., "no reports of spread from person to person or to healthcare workers.") 

CDC recommends  cautious approach to symptomatic patients with a history of travel to Wuhan." Patients should don surgical masks, be evaluated in private rooms with door closed. And medical personnel should use contact precautions and wear an N95 disposable facepiece respirator.

Watch - Level 1, Practice usual precautions

There is a cluster of cases of pneumonia in Wuhan, China. The cause is not yet known, nor is the mode of transmission. The cluster is centered at the Wuhan South China Seafood City (also called the South China Seafood Wholesale Market and the Hua Nan Seafood Market). The market has been closed since [1 Jan 2020] for cleaning and disinfection. Travelers to Wuhan, China, should avoid living or dead animals, animal markets, and contact with sick people.

The situation is evolving. This notice will be updated as more information becomes available.

What is the current situation?

There is a cluster of cases of pneumonia in Wuhan, China. As of [5 Jan 2020], local, provincial, and national health commissions in China have reported a total of 59 cases with no deaths.

The cluster is centered at the Wuhan South China Seafood City (also called the South China Seafood Wholesale Market and the Hua Nan Seafood Market). In addition to seafood, the market sells chickens, bats, marmots, and other wild animals. The market has been closed since [1 Jan 2020] for cleaning and disinfection. Health authorities in China are monitoring more than 150 close contacts for illness. To date, there have been no reports of spread from person to person or to healthcare workers.

Symptoms include fever and difficulty breathing. Though the cause of this cluster is unknown, there is concern that it is a virus. Local authorities have reported negative laboratory results for seasonal influenza, avian influenza, adenovirus, and 2 specific coronaviruses known to cause respiratory illness (severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS]).

What can travelers do to protect themselves?

Travelers to Wuhan should: Avoid animals (alive or dead), animal markets, and products that come from animals (such as uncooked meat). Avoid contact with sick people. Wash hands often with soap and water. If you traveled to Wuhan and feel sick, you should: Stay home. Except for seeking medical care, avoid contact with others. Don't travel while sick. Seek medical care right away. Before you go to a doctor's office or emergency room, call ahead and tell the doctor about your recent travel and your symptoms. Cover your mouth and nose with a tissue or your sleeve (not your hands) when coughing or sneezing.

Clinician information As of this posting, case-patients in the cluster reportedly have had fever, difficulty breathing, and bilateral lung infiltrates on chest radiograph. For patients with similar respiratory symptoms who recently traveled to Wuhan, consider pneumonia related to the cluster and notify infection control personnel and your local health department immediately.

Although the etiology and transmission dynamics have yet to be determined, the CDC recommends a cautious approach to symptomatic patients with a history of travel to Wuhan. A such patients to don a surgical mask as soon as they are identified. Conduct their evaluation in a private room with the door closed. Personnel entering the room to evaluate the patient should use contact precautions and wear an N95 disposable facepiece respirator. For patients admitted for inpatient care, implement contact and airborne isolation precautions, in addition to standard precautions, until further information becomes available.


20200108 Promed - Undiagnosed pneumonia - China Hong Kong surveillance, About USA CDC alert on Jan 6.


20200108 Promed- Undiagnosed pneumonia - China. Novel coronavirus identified. 

            Key points:



Health authorities in Singapore and Hong Kong, cities that have direct flights from Wuhan, have issued alerts and quarantined patients travelling from the region who show signs of fever or breathing difficulties.

In Hong Kong on Tuesday [7 Jan 2020], the government said it was taking precautions against a "severe respiratory disease associated with a novel infectious agent" that it is seeking to make a statutory notifiable infectious disease, meaning doctors would need to report any suspected cases, and patients evading quarantine could be fined or jailed.

The Chinese Center for Disease Control and Prevention is expected to make an announcement of its findings in the coming days, a person familiar with the matter said. The Chinese CDC couldn't be reached for comment late Tuesday [7 Jan 2020].

The pattern of the unexplained pneumonia cases linked to the market selling seafood and also live game strongly suggests that this is a novel microbe jumping from animal to human, said K.Y. Yuen, Chair Professor of Infectious Diseases at the University of Hong Kong's Faculty of Medicine.

The Wuhan strain is similar to bat coronaviruses that were a precursor to SARS, according to a person familiar with the new findings.

Given the marked advances in hospital isolation facilities, infection-control training and laboratory diagnostic capabilities in the past two decades, it is unlikely that this outbreak will lead to a major 2003-like epidemic, said K.Y. Yuen, Chair Professor of Infectious Diseases at the University of Hong Kong's Faculty of Medicine.

In Wuhan, which has China's 1st Biosafety Level 4 laboratory - a specialized research laboratory that deals with potentially deadly infectious agents like Ebola - the market at the center of investigations has been shut down since [1 Jan 2020].

In Hong Kong, badly hit by the SARS virus, which claimed 299 lives locally in 2003, residents have donned surgical masks on the streets and public transport in recent days, despite no local cases of the Wuhan infection being confirmed



20200109 WHO -- Statement regarding cluster of pneumonia cases in Wuhan, China.pdf 





20200111 In China Yong-Zhen Zhang’s lab (a Level 3 biosafety facility) publishes the genome sequence of the novel coronavirus (later designated SARS-CoV-2) associated with the emerging outbreak in China on See reply thread for link to genome sequence published (note, corrected versions were subsequently published) After failing to receive a response, on the 11th Zhang, via collaborating colleague Edward C. Holmes at University of Sydney, directly submits the sequence to GenBank and posts notice on After Zhang's data is published to the world on open platforms, Chinese officials announce they will share the data. Zhang's lab is closed the next day (January 12) for "rectification" by order of the Shanghai Health Commission. Source: South China Morning Post (see 20200228 SMCP article in reply thread below)


Yong-Zhen Zhang’s post genomic sequence of the novel coronavirus$=seqview


20200112 WHO - Statement Novel Coronavirus

Key Points:

"WHO is reassured of the quality of the ongoing investigations and the response measures implemented in Wuhan, and the commitment to share information regularly."

"At this stage, there is no infection among healthcare workers, and no clear evidence of human to human transmission. The Chinese authorities continue their work of intensive surveillance and follow up measures, as well as further epidemiological investigations.

China shared the genetic sequence of the novel coronavirus on 12 January, which will be of great importance for other countries to use in developing specific diagnostic kits. 


20200114 WHO- Coronavirus No evidence of human-to-human transmission


20200116 SCIENCE CHINA Life Sciences, Volume 63, Issue 3: 457-460(2020)  Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission


20200122 bioRxiv preprint -- Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin (later printed 3 February in Nature - A pneumonia outbreak associated with a new coronavirus of probable bat origin

Key Points: More on the natural reservoir… "Full-length genome sequences were obtained from 5 patients at the early stage of the outbreak. They are almost identical to each other and share 79.5% sequence identify to SARS-CoV. Furthermore, it was found that 2019-nCoV is 96% identical at the whole genome level to a bat coronavirus. The pairwise protein sequence analysis of 7 conserved non-structural proteins show that this virus belongs to the species of SARSr-CoV. The 2019-nCoV virus was then isolated from the bronchoalveolar lavage fluid of a critically ill patient, which can be neutralized by sera from several patients. Importantly, we have confirmed that this novel CoV uses the same cell entry receptor, ACE2, as SARS-CoV."


20200122 On 22 January, the members of the World Health Organization (WHO) Emergency Committee expressed divergent views on whether the novel coronavirus outbreak constituted a Public Health Emergencies of International Concern (PHEIC) but decided the event did not constitute a PHEIC.


20200123  MIT Technology Review - Virus in Chinese outbreak is closest to one from bats, not snakes


20200123 WHO  -Statement on the meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus 2019 (n-CoV) on 23 January 2020

Key Points: 

WHO welcomed the efforts made by China to investigate and contain the current outbreak.

WHO decided it was still too early to declare a  Public Health Emergency of International Concern (PHEIC), given its restrictive and binary nature.

All countries should be prepared for containment, including active surveillance, early detection, isolation and case management, contact tracing and prevention of onward spread of 2019-nCoV infection, and to share full data with WHO.

Countries are required to share information with WHO according to the International health Regulations (IHR).


20200123 BioRxiv - Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin (later republished in Nature)


20200124 Lancet -- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China


20200124 Representation epidemiological exposures for the 41 patients discussed in 20200124 Lancet -- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China 20200124 Representation epidemiological exposures for the 41 patients discussed in 20200124 Lancet -- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China  epresentation epidemiological exposures for the 41 patients discussed in 20200124 Lancet -- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China The data and the Ro characteristics of the outbreak indicate that the Wuhan market may not have been the site where the virus made the leap into humans. It was certainly an early point of dissemination but the actual origin could have been elsewhere in the region.




20200124 NEJM - A Novel Coronavirus from Patients with Pneumonia in China, 2019  


20200124 K. Lee Lerner comment::

The early calculations of the Ro of this disease ranges between 1.4 to 2.5. This means it’s transmissible and will spread. The fatality rate is about 3%. This makes this virus much more like the pandemic 1918 flu that killed millions than SARS. But. but.. but.. we now have clinical supportive measures and antivirals that did not exist in 1981 and so this will be an interesting test of the global health response. What worries me is that it is already showing 4th generation changes in transmissibility (IIRC SARS never went past 2nd generation)— that means this Wuhan coronavirus loves humans and is finding ways to become more easily transmissible (hence the Ro might change).”



A key thing yet unknown about 2019-nCoV is whether it is transmissible before symptoms appear. SARS was stemmed in part because it wasn't very transmissible before symptoms appeared. Hence people knew they were sick and sought treatment and/or could be quarantined before spreading the virus. How quickly health care workers can get on top of 2019-nCOV will depend greatly on when symptoms of exposure (illness from exposure) first appear.



20200124 Updated WHO advice for international traffic in relation to the outbreak of the novel coronavirus 2019-nCoV


20200124 A comment in Lancet highlights the important of accurate data sharing in response to these outbreaks …

Wiley, Elsevier, Springer, and other major publishers and university presses, open their archives with regard to articles needed to understand the 2019-nCOv outbreak. Following a consensus developed since SARS that the best way to defeat misinformation is with accurate, vetted, well-sourced information that reflects the  best science and, most importantly, the evolution of scientific knowledge. 

In so doing publishers and other entities are following the important recommendations set forth following the Event 201 exercises last October at the Johns Hopkins Bloomberg School’s Center for Health Security. Such openness by researchers and publishers is essential to combating misleading information.

Due to misinterpretation of the exercise the Event 201 organizers issued the following clarification:  Statement about nCoV and our pandemic exercise: "In October 2019, the Johns Hopkins Center for Health Security hosted a pandemic tabletop exercise called Event 201 with partners, the World Economic Forum and the Bill & Melinda Gates Foundation. Recently, the Center for Health Security has received questions about whether that pandemic exercise predicted the current novel coronavirus outbreak in China. To be clear, the Center for Health Security and partners did not make a prediction during our tabletop exercise. For the scenario, we modeled a fictional coronavirus pandemic, but we explicitly stated that it was not a prediction. Instead, the exercise served to highlight preparedness and response challenges that would likely arise in a very severe pandemic. We are not now predicting that the nCoV-2019 outbreak will kill 65 million people. Although our tabletop exercise included a mock novel coronavirus, the inputs we used for modeling the potential impact of that fictional virus are not similar to nCoV-2019." 

As of this date,  making the round on alternative media -- and occasionally rising to the the level of mainstream broadcasters like the BBC -- are assertions (offered without evidence, without context, or contrary to existing evidence) that:  


(1)  2018-nCoV hss a citing a 25% lethality rate for 2019-nCoV;

(2)  the outbreak is a CIA plot to overthrow the Chinese government;

(3)  the outbreak was the result of an accidental release from the "Wuhan Virology Institute". This would be the most difficult to disprove and so holds the most promise for a void in which conspiracy theories might gain traction. Moreover, because accidental releases do happen, an accidental release is possible; Genetically engineered viruses (shaped deliberately or via experimentation) are relatively easy to distinguish from those shaped by evolutionary mechanisms.

(4)  the Chinese might consider nuking Wuhan to eliminate the virus.



20200126 Science -- Wuhan seafood market may not be source of novel virus spreading globally


20200126 K. Lee Lerner Comment on China Health official’s assessment that 2109-nCOv is transmissible before symptoms appear (See BBC article cited): 

“London Imperial College estimated the 2019-nCOv Ro at 2.6 as of 18 January. Not good news. To stop a virus with this Ro form spreading China will need to block at least 60 percent of those currently infected from infecting others. Hence the largest quarantine in history. The latest estimates regarding 2019-nCOv transmissibility greatly complicates this effort because control of the disease relies on isolation before transmission. Many people are not put into isolation until they are symptomatic, and the latest --but still preliminary--reports on 2109-nCOv are that it is transmissible before symptoms appear.”


20200126 BBC - China coronavirus 'spreads before symptoms show'



20200129 Infection, Genetics and Evolution (via ScienceDirect) -- Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event)   Key Point: Evidence that the hypothesis of emergence of 2019-nCoV as a result of a recent recombination event is rejected.



20200129 Lancet - Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China/a descriptive study


20200130 Lancet - Genomic characterization and epidemiology of 2019 novel coronavirus/ implications for virus origins and receptor binding


20200130 As of 30 January, 2020  Coronavirus Confirmed Cases: 8,288  Deaths: 171 Fatality rate per 100 cases = 2.06.  Here is a vetted site from JHU (with WHO, CDC, NHC and DXY data) that helps visualize the most current data…

No photo description available.


20200130 Issues in Science and technology - Clarity, Please, on the Coronavirus Statistics | Issues in Science and Technology.pdf


20200131 NEJM - First Case of 2019 Novel Coronavirus in the United States | NEJM.pdf



February 2020



20200201 IJID - The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China - International Journal of Infectious Diseases.pdf


20200201 EJMED - View of The Emerging of The 2019 Novel Coronavirus 2019-nCoV.pdf


20200203 Nature - A New Coronavirus Associated With Human Respiratory Disease in China

20200214 AAAS BioWorld - Researchers trace COVID-19’s family tree to battle outbreak and infodemic.


"From everything I’ve looked at, there is zero evidence for genetic engineering; it looks like normal evolution,” said Trevor Bedford, a computational biologist at Fred Hutchinson Cancer Research Center,

A key paper promoted by  conspiracy theory proponents that SARS-CoV-2 was genetically engineered was never peer reviewed, had shoddy research, and was quickly withdrawn from Biorxiv.

"Based on the genetic analysis, the likelihood is that the virus was transmitted by a bat to another mammal between 20 and 70 years ago. That as-yet-unidentified intermediary passed the virus on to its first human host in the city of Wuhan in late November or early December 2019." 

See also:  Generic epidemiology for SARS-CoV-2


20200217 CCDC - The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China CDC.


20200218 Lancet - Li Wenliang Obituary  "Ophthalmologist who warned about the outbreak of COVID-19. Born in Beizhen, China, on Oct 12, 1986, he died after becoming infected with SARS-CoV-2 in Wuhan, China, on Feb 7, 2020, aged 33 years.  On Dec 30, 2019, Li Wenliang sent a message to a group of fellow doctors warning them about a possible outbreak of an illness that resembled severe acute respiratory syndrome (SARS) in Wuhan, Hubei province, China, where he worked. Meant to be a private message, he encouraged them to protect themselves from infection. Days later, he was summoned to the Public Security Bureau in Wuhan and made to sign a statement in which he was accused of making false statements that disturbed the public order.



20200219 NID - Field Briefing/ Diamond Princess COVID-19 Cases


20200226 Science - ‘A completely new culture of doing research.’ Coronavirus outbreak changes how scientists communicate | Science | AAAS.pdf


20200227 JACEP (via Wiley Online Library)l - Coronavirus disease 2019/ International public health considerations - Greene - - Journal of the American College of Emergency Physicians.pdf


20200228 Lancet - Feasibility of 20200228 Lancet - Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts.


20200228 NEJM - Clinical Characteristics of Coronavirus Disease 2019 in China | NEJM


20200228 NEJM - Bill Gates,  Responding to Covid-19 — A Once-in-a-Century Pandemic? | NEJM.pdf

Related Article: RPP_20201019 JHU, WEF, BMGF - Event 201, Public-Private Cooperation for  Pandemic Preparedness.pdf


20200229 MedRxiv (Preprint) - Evaluation of the clinical characteristics of suspected or confirmed cases of COVID-19 during home care with isolation/ A new retrospective analysis based on O2O | medRxiv.pdf


20200229 Science - In bid to rapidly expand coronavirus testing, U.S. agency abruptly changes rules | Science | AAAS.pdf


March 2020


20200307 Lancet - Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19 - The Lancet.pdf Excerpt: “We stand together to strongly condemn conspiracy theories suggesting that COVID-19 does not have a natural origin. Scientists from multiple countries have published and analysed genomes of the causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and they overwhelmingly conclude that this coronavirus originated in wildlife as have so many other emerging pathogens. This is further supported by a letter from the presidents of the US National Academies of Science, Engineering, and Medicine and by the scientific communities they represent. Conspiracy theories do nothing but create fear, rumours, and prejudice that jeopardise our global collaboration in the fight against this virus.”


20200309 JAMA - Diagnostic Testing for the Novel Coronavirus | Global Health | JAMA | JAMA Network.pdf


20200310 Annals Int Med -The Incubation Period of COVID-19 From Publicly Reported Confirmed Cases | Annals of Internal Medicine | American College of Physicians.pdf


20200311 Scientific American - How China's "Bat Woman" Hunted Down Viruses from SARS to the New Coronavirus - Scientific American.pdf  Wuhan-based virologist Shi Zhengli has identified dozens of deadly SARS-like viruses in bat caves, and she warns there are more out there. 


20200313 Nature - How much is coronavirus spreading under the radar?.pdf 


20200313 Ariadne Labs, By Asaf Bitton, MD, MPH (via Medium)  - Social Distancing/ This is Not a Snow Day


20200314 Emerging Microbes and Infections - Full article/ A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence/ lessons from other pathogenic viruses.pdf


20200315 The Independent - When will a coronavirus vaccine be ready? | Comment: Scientifically sound overview of the process and perils.


20200316 Science - Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2) | Science.pdf


20200316 Imperial College COVID-19 Response Team Report  9 - Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand.pdf



20200316 Science -- Disease experts call for nationwide closure of U.S. schools and businesses to slow coronavirus | Science | AAAS 



20200317 NATURE- The proximal origin of SARS-CoV-2 | Nature Medicine  Key Points: “Our analyses clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus,”


20200317 Scripps Research - The COVID-19 coronavirus epidemic has a natural origin, scientists say | Scripps Research.


20200317 Science - Coronavirus cases have dropped sharply in South Korea. What’s the secret to its success? | Science | AAAS


20200317 NEJM - Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington | NEJM.pdf 



20200317 JAMA - Coronavirus Disease 2019 (COVID-19) in Italy | Critical Care Medicine | JAMA | JAMA Network 



20200317 NEJM - Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 | NEJM.pdf


20200318 NEJM -A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM.pdf Excerpt: In conclusion, we found that lopinavir–ritonavir treatment did not significantly accelerate clinical improvement, reduce mortality, or diminish throat viral RNA detectability in patients with serious Covid-19.


20200318 NEJM - SARS-CoV-2 Infection in Children | NEJM.pdf


20200318 Nature - Coronavirus vaccines - five key questions as trials begin.pdf


20200319 AP - China exonerates doctor reprimanded for warning of virus.



20200319 Nature - Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China | Nature Medicine.pdf 



20200320 BioRxiv (NPR Preprint) - An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus | bioRxiv   Abstract Excerpt: Based on study in mice:  “Herein, we show that the ribonucleoside analog β-D-N4-hydroxycytidine (NHC, EIDD-1931) has broad spectrum antiviral activity against SARS-CoV 2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to another nucleoside analog inhibitor.“


20200320 *International Journal of Antimicrobial Agents (Preprint via Science Direct) - Hydroxychloroquine and azithromycin as a treatment of COVID-19/ results of an open-label non-randomized clinical trial - *SEE CONTRARY STATEMENTS ABOUT THIS FRENCH STUDY.


20200322 Commentary:  Lerner, K. Lee. “Hydroxychloroquine and the allure and perils of abandoning evidence-based science and policy in times of crisis. (SARS-CoV-2, Covid-19 pandemic)” Online at: 



April 2020


20200401 Lancet - Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts - The Lancet Global Health.pdf



Key Point: A preliminary not-yet--peer-reviewed preliminary report of research said, In summary, “pigs and chickens could not be productively infected by SARS-CoV-2 under these experimental conditions, an information that is relevant for a solid risk assessment. Furthermore, virus replication in ferrets resembles the situation of a mild human infection and this species might serve as a useful model for further studies e.g. testing vaccines or antivirals.” Includes references to prior reports of infections in cats and other animals.



20200410 STAT - Covid-19 'immunity certificates'/ practical and ethical conundrums - STAT.pdf 


20200410 MedRxiv (NPR Preprint) - Efficacy of hydroxychloroquine in patients with COVID-19/ results of a randomized clinical trial | medRxiv Abstract Excerpt:  “Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19.... Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia.  Note: NPR Non-peer reviewed preprint of s study conducted in China.


20200413 CDC MMWR - Timing of Community Mitigation and Changes in Reported COVID-19 and Community Mobility ― Four U.S. Metropolitan Areas, February 26–April 1, 2020 | MMWR.pdf


20200414 Science - Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period See also:  Harvard Gazette - Warm weather may have no impact on COVID-19 – Harvard Gazette

[K. Lee Lerner Comment:] SARS-CoV2 is a novel coronavirus so, in theory, everyone is vulnerable. They may not however be equally vulnerable.  Preexisting antibody based theories are not outlandish, but it not likely to be the reason Africa is apparently lagging in terms of cases and deaths. For example, some studies suggest infection with other coronaviruses (HKU1 and OC43 may convey initial protection against SARS-CoV-2 infection. However, those viruses trigger only short- term immunity, usually under a year and so if there is something similar in play in Africa the lag phenomena may be short-lived. Most epidemiologists suspect that Africa's apparent case lag is a combination of many factors including limited testing, historic reporting irregularities, varying criteria for attributing deaths, etc. Warm weather can't be discounted, as it may tamp down the infection spread, but the data is still inconclusive. Coronaviruses are currently infecting people in warm climates, and if the rate of spread subsides in summer months it may roar back in the winter, possibly with a mutated virus. Something similar happened in 1918 where a mutated strain proved more lethal.  The United Nations Economic Commission for Africa anticipates Africa will follow Brazil and Latin America as a global hotspot, Based on Imperial College London, they are predicting a minimum of 300,000 deaths in Africa this year with worst case scenarios ranging to 3.3 million deaths. Africa already faces severe strains from malaria and other diseases and so damage to fragile health care systems due to the COVID-19 pandemic could greatly exacerbate deaths due to other causes.


20200414 Harvard Crimson - As Coronavirus Spreads, False Theories Linking Harvard Professor Lieber to Disease’s Origin Proliferate Online | The Harvard Crimson.pdf



20200414 WAPO - State Department cables in January 2018 warned of safety issues at Wuhan lab studying bat coronaviruses.

Related Articles (See Appendix for relevant prior publications (RPP) published prior to December 2019) 

RPP_20151112 Nature - Engineered bat virus stirs debate over risky research / Nature News & Nature News and Comment  " Editors’ note, March 2020: We are aware that this story is being used as the basis for unverified theories that the novel coronavirus causing COVID-19 was engineered. There is no evidence that this is true; scientists believe that an animal is the most likely source of the coronavirus." 

RPP_20180912 Emerg Microbes Infect - Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats



0200415 Nature - China is tightening its grip on coronavirus research 


20200415 AP - China didn't warn publicly of the pandemic for 6 key days. 

Key Points:  As the record above documents, the delay was not a singular event but part of a pattern and practice of delay and deception In sum, such delays and deceptions cost the world far more than just six days at at time early in the outbreak —especially during a holiday season with people traveling — when every day was crucial.


20200415 CBS Boston - CDC reviewing ‘stunning’ universal testing results from Boston homeless shelter Key Points : "We don’t have enough data on universal testing to understand how many asymptomatic people are contagious.”  "Of the 397 people tested, 146 people tested positive. Not a single one had any symptoms." "Stunning" because this is a population with high co-morbidities.

20200416 AP - China's virus death toll revised up sharply after review.pdf


20200416 Reuters - Coronavirus clue? Most cases aboard U.S. aircraft carrier are symptom-free - Reuters


20200416 MedRxiv (NPR Preprint) - A serological assay to detect SARS-CoV-2 seroconversion in humans | medRxiv.pdf


20200416 Cyberscoop - Coronavirus scientists are big targets for foreign cyber-espionage, FBI says.


20200417 Johns Hopkins Biosecurity - Global Progress on COVID-19 Serology-Based Testing.pdf


20200417 Science - How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes | Science | AAAS


20200417 Xinhua -Full text of Wuhan's notification on revising numbers of confirmed COVID-19 cases, deaths - 

Key points:

China raises the total number of confirmed COVID-19 cases in Wuhan as of  16 Apr 2020 by 325 to 50 333, and the number of fatalities up from 1290 to 3869.

The revision raises Wuhan's confirmed case fatality percentage from 2.6 percent to 7.7 percent, a figure much more in line with data from Europe and America. 

The reasons cited for data discrepancies:

(1) "a surging number of patients at the early stage of the epidemic overwhelmed medical resources and the admission capacity of medical institutions. Some patients died at home without having been treated in hospitals;

(2) during the height of their treating efforts, hospitals were operating beyond their capacities and medical staff were preoccupied with saving and treating patients, resulting in belated, missed and mistaken reporting;

(3) due to a rapid increase of designated hospitals for treating COVID-19 patients, including those administered by ministries, Hubei Province, Wuhan city and its districts, those affiliated to companies, as well as private hospitals and makeshift hospitals, a few medical institutions were not linked to the epidemic information network and failed to report their data in time;

(4) the registered information of some of the deceased patients was incomplete, and there were repetitions and mistakes in the reporting."

KLL Comment:  China has "corrected" for Wuhan, not for the country. Now that the CCP has cover from stark figures elsewhere (and global eye turned inward) they will gradually keep correcting their case and death counts to make them more mathematically plausible. The math still doesn't work out with regard to the Ro and case fatality rates observed elsewhere. China has a history of going big on such deceptions. When between 2 to 20 million people died during the Cultural Revolution (and the range of those estimates ought to tell you everything you need to know) the CCP initially claimed a million dead. When between 15 to 45 million died during the Great Famine (and the range of those estimates ought to tell you everything you need to know), the CCP started at one million before —after many years — confessing to the death of at least 15 million people. Look for the same magnitude of errors, and dedication to the truth in counting COVID -19 victims.  See also: AP-China’s virus death toll revised up sharply after review


20200420 Contagion - Discovering COVID-19 Countermeasures Without Discarding Scientific Method.

20200420 Journal of Biomolecular Structure and Dynamics -- Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment.


20200421 Santa Clara County Public Health — County of Santa Clara Identifies Three Additional Early COVID-19 Deaths  See Also: Reuters - First U.S. coronavirus death occurred in early February in California


20200422 MedRXiv (Not yet peer reviewed) -- Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19.

KLL Comment: U.S. President Trump and others (including a mix of physicians and political commentators  in China, Europe and the U.S.) have recently promoted use of the anti-malarial drug hydroxychloroquine for treatment of COVID-19. A new study (not yet peer reviewed but a more fundamentally sound study than earlier ones cited to tout the drug) based on analysis of data from 368 patients found significantly elevated death rates in those who received the drug, even when combined with the antibiotic azithromycin. The U.S. National Institute of Health has recommended doctors not use the malaria drug, which has the potential to induce cardiac arrhythmia.  See also: Reuters - Drug championed by Trump for coronavirus shows no benefit, possible harm in study awaiting validation and Bloomberg - U.S. Virus Guidelines Reject Trump-Backed Drug Combination



20200423 Science - Against pandemic research exceptionalism | Science. Abstract: Crises are no excuse for lowering scientific standards


20200425 FDA -- FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems.pdf


20200502 Lancet -- A global health crisis? No, something far worse - The Lancet.pdf


20200504 Nature -Profile of a killer/ the complex biology powering the coronavirus pandemic.


20200505 Infection, Genetics, Evolution -- Emergence of genomic diversity and recurrent mutations in SARS-CoV-2 


(K. Lee Lerner Comment] "This rules out any scenario that assumes SARS-CoV-2 may have been in circulation long before it was identified, and hence have already infected large proportions of the population." — Francois Balloux, University College London 

It is important to note that for a number of reasons there are claims circulating that the virus was in Europe and the US before what we now consider the first reported cases. This is both possible and reasonable. 

The first documented case in China with regard to the onset of symptoms was December 1, 2019 meaning the infection could easily have been circulating in China in November. As asymptomatic carriers can still be contagious, it is possible that infected travelers from China started spreading the virus globally as early as late November 2019. 

Resulting infections —still at low levels in terms of numbers of cases -- might have been confused with flu in December. This would account for the number of early patients who were confirmed positive for SARS-CoV-2 who had no relationship to the seafood market in Wuhan.

20200521 Harvard University / Harvard Medical School - Weather Conditions and COVID-19 Transmission- Estimates and Projections  Preprint (not yet peer reviewed) at:  See also related coverage of research at Will Hot Weather Kill the Coronavirus Where You Live? at



20200522 CDC- How COVID-19 Spreads.  

K. Lee Lerner comment:  I'm finding this CDC Covid-19 guidance update (and news articles based on it) passed around to discredit the CDC (or science in general) because the CDC guidance now states that SARS-CoV-2 does not spread easily via touching surfaces or objects.

This is nothing new. Very early on most experts discounted surface transmission as a LEADING source of transmission. Transmission from contaminated surfaces is also not thought to be a leading cause of transmission with seasonal flu, but SARS-CoV-2 was/is a novel coronavirus and not the flu and so, out of an abundance of caution and until transmission could be better studied, guidance was issued to guard against both surface transmission and transmission of SARS-CoV-2 from contact and respiratory droplets.

An increasing amount of research is showing those early assumptions to be correct. The data now CONFIRMS that the MAIN way Covid-19 spreads is via contact and contaminated reparatory droplets inhaled and/or transmitted from foamites (which are located on surfaces).

While surface transmission is again not thought to be a leading source of transmission, it is, however, still possible and certainly accounts for some cases (the percentage remains uncertain). It has been known from the beginning — from the structure of the virus itself — that this virus was not a hardy surface survivor like noroviruses.

The CDC still recommends that people "routinely clean and disinfect frequently touched surfaces." 

The CDC also still recommends that you should take every precaution to guard against touching potentially contaminated surfaces and then touching your mouth, nose, or eyes.

Nothing has changed regarding that guidance.

The CDC and other health experts have never said that surface transmission was the main way the virus spreads only that it was (and is) a possible way for the virus to spread. 

Anyone who uses an advancement in science knowledge — or anyone claim ling that the original guidance was "wrong"  — is, at best, simply scientifically illiterate because this is how science works! From what I have observed, it is much more likely that those who advance such arguments are  deliberately creating a strawman argument to advance some non-science, non-evidence-based, agenda.  Beware.


20200522 Lancet - Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19/ a multinational registry analysis. 

Excerpts:  “Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit. Although generally safe when used for approved indications such as autoimmune disease or malaria, the safety and benefit of these treatment regimens are poorly evaluated in COVID-19.”: Interpretation: We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.”


Relevant Prior Posts (RPP)


rpp_ 20141208 Nature - Gain-of-function experiments/ time for a real debate | Nature Reviews Microbiology 

rpp_ 20181004 PLOS Pathogens - Inoculating science against potential pandemics and information hazards 

rpp_ 20190710 IOP Science Biofabrication - Multi-cellular engineered living systems/ building a community around responsible research on emergence






20191230_promed_-_undiagnosed_pneumonia_-_china_hu-_rfi_archive_number-_20191230.6864153.pdf78 KB
20200101_scmp_-_world_health_organisation_in_touch_with_beijing_after_mystery_viral_pneumonia_outbreak_01.pdf1.12 MB
20200102_promed_-undiagnosed_pneumonia_-_china_hubei_01-_wildlife_sales_market_closed_request_for_information.pdf59 KB
20200103_promed_-_undiagnosed_pneumonia_-_china_hu_02-_updates_other_country_responses_rfi_.pdf71 KB
20200105_promed_-_undiagnosed_pneumonia_-_china_updates_sars_mers_ruled_out_who_rfi_.pdf78 KB
20200106_cdc_-_watch_notice_01.pdf26 KB
20200108_promed_-_undiagnosed_pneumonia_-_china_novel_coronavirus_identified_.pdf64 KB
20200108_promed_-_undiagnosed_pneumonia_-_china_hong_kong_surveillance_usa_cdc_alert.pdf64 KB
20200109_uminn_-_pressure_builds_on_china_to_share_info_on_new_coronavirus_cidrap.pdf265 KB
20200109_who_statement_regarding_cluster_of_pneumonia_cases_in_wuhan_china_01.pdf85 KB
20200110_promed_-_undiagnosed_pneumonia_-_china_hubei_09-_novel_coronavirus_more_information_first_fatality.pdf73 KB
20200112_who_-_statement_novel_coronavirus_-_china.pdf136 KB
20151112_nature_-_engineered_bat_virus_stirs_debate_over_risky_research_nature_news_comment.pdf113 KB
20200116_china_life_sceinces_-_evolution_of_the_novel_coronavirus_from_the_ongoing_wuhan_outbreak_and_modeling_of_its_spike_protein_for_risk_of_human_transmission_01.pdf1.06 MB
20200122_biorxiv_preprint_later_printed_nature_20200203_-_discovery_of_a_novel_coronavirus_associated_with_the_recent_pneumonia_outbreak_in_3_humans_and_its_potential_bat_origin_.pdf1.41 MB
20200123_mit_-_virus_in_chinese_outbreak_is_closest_to_one_from_bats_not_snakes_mit_technology_review.pdf1.02 MB
20200123_who_-statement_on_the_meeting_of_the_international_health_regulations_2005_emergency_committee_regarding_the_outbreak_of_novel_coronavirus_2019_n-cov_on_23_january_2020_01.pdf126 KB
20200123_biorxiv_-_discovery_of_a_novel_coronavirus_associated_with_the_recent_pneumonia_outbreak_in_humans_and_its_potential_bat_origin_biorxiv.pdf295 KB
20200124_nejm_-_a_novel_coronavirus_from_patients_with_pneumonia_in_china_2019_01.pdf626 KB
20200124_lancet_-_clinical_features_of_patients_infected_with_2019_novel_coronavirus_in_wuhan_china_-_the_lancet_01.pdf408 KB
20200124_who_-_updated_who_advice_for_international_traffic_in_relation_to_the_outbreak_of_the_novel_coronavirus_2019-ncov_01.pdf127 KB
20200126_science_-_wuhan_seafood_market_may_not_be_source_of_novel_virus_spreading_globally_science_aaas.pdf1003 KB
20200126_bbc_-_china_coronavirus_spreads_before_symptoms_show_-_bbc_news.pdf647 KB
20200129_lancet_-_epidemiological_and_clinical_characteristics_of_99_cases_of_2019_novel_coronavirus_pneumonia_in_wuhan_chinaa_descriptive_study.pdf517 KB
20200129_infection_genetics_and_evolution_via_sciencedirect_-_full-genome_evolutionary_analysis_of_the_novel_corona_virus_2019-ncov_rejects_the_hypothesis_of_emergence_as_a_result_of_a_recent_recombination_event.pdf358 KB
20200130_lancet_-_genomic_characterisation_and_epidemiology_of_2019_novel_coronavirus_implications_for_virus_origins_and_receptor_binding_01.pdf545 KB
20200130_issues_in_science_and_technology_-_clarity_please_on_the_coronavirus_statistics_issues_in_science_and_technology.pdf178 KB
20200131_nejm_-_first_case_of_2019_novel_coronavirus_in_the_united_states_nejm.pdf629 KB
20200201_ijid_-_the_continuing_2019-ncov_epidemic_threat_of_novel_coronaviruses_to_global_health_-_the_latest_2019_novel_coronavirus_outbreak_in_wuhan_china_-_international_journal_of_infectious_diseases.pdf395 KB
20200201_ejmed_-_view_of_the_emerging_of_the_2019_novel_coronavirus_2019-ncov.pdf1 KB
20200203_nature_-_a_pneumonia_outbreak_associated_with_a_new_coronavirus_of_probable_bat_origin_nature.pdf1.16 MB
20200203_nature_-_a_new_coronavirus_associated_with_human_respiratory_disease_in_china_01.pdf141 KB
20200214_aaas_bioworld_-_researchers_trace_covid-19s_family_tree_to_battle_outbreak_and_infodemic.pdf1.37 MB
20200217_ccdc_-_the_epidemiological_characteristics_of_an_outbreak_of_2019_novel_coronavirus_diseases_covid-19_-_china_cdc.pdf2.96 MB
20200218_lancet_-_li_wenliang_obit_01.pdf648 KB
20200219_nid_-_field_briefing_diamond_princess_covid-19_cases.pdf169 KB
20200226_science_-_a_completely_new_culture_of_doing_research._coronavirus_outbreak_changes_how_scientists_communicate_science_aaas.pdf1.79 MB
20200227_jacep_via_wiley_online_libraryl_-_coronavirus_disease_2019_international_public_health_considerations_-_greene_-_-_journal_of_the_american_college_of_emergency_physicians.pdf577 KB
20200228_scmp_-_chinese_laboratory_that_first_shared_coronavirus_genome_with_world_ordered_to_close_for_rectification_hindering_its_covid-19_research_south_china_morning_post.pdf707 KB
20200228_lancet_-_feasibility_of_controlling_covid-19_outbreaks_by_isolation_of_cases_and_contacts_01.pdf5.38 MB
20200228_nejm_-_clinical_characteristics_of_coronavirus_disease_2019_in_china_nejm.pdf693 KB
20200228_nejm_-_bill_gates_responding_to_covid-19_-_a_once-in-a-century_pandemic_nejm.pdf446 KB
20200229_medrxiv_preprint_-_evaluation_of_the_clinical_characteristics_of_suspected_or_confirmed_cases_of_covid-19_during_home_care_with_isolation_a_new_retrospective_analysis_based_on_o2o_medrxiv.pdf162 KB
20200229_science_-_in_bid_to_rapidly_expand_coronavirus_testing_u.s._agency_abruptly_changes_rules_science_aaas.pdf1.46 MB
20200307_lancet_-_statement_in_support_of_the_scientists_public_health_professionals_and_medical_professionals_of_china_combatting_covid-19_-_the_lancet.pdf168 KB
20200309_jama_-_diagnostic_testing_for_the_novel_coronavirus_global_health_jama_jama_network.pdf164 KB
20200310_annals_int_med_-the_incubation_period_of_covid-19_from_publicly_reported_confirmed_cases_annals_of_internal_medicine_american_college_of_physicians.pdf923 KB
20200311_scientific_american_-_how_chinas_22bat_woman22_hunted_down_viruses_from_sars_to_the_new_coronavirus_-_scientific_american.pdf1.1 MB
20200313_nature_-_how_much_is_coronavirus_spreading_under_the_radar.pdf200 KB
20200313_ariadne_labs_by_asaf_bitton_md_mph_via_medium_-_social_distancing_this_is_not_a_snow_day.pdf710 KB
20200314_emerging_microbes_and_infections_-_full_article_a_tug-of-war_between_severe_acute_respiratory_syndrome_coronavirus_2_and_host_antiviral_defence_lessons_from_other_pathogenic_viruses.pdf537 KB
20200315_the_independent_-_when_will_a_coronavirus_vaccine_be_ready_theindependentbd.com_.pdf952 KB
20200316_science_-_substantial_undocumented_infection_facilitates_the_rapid_dissemination_of_novel_coronavirus_sars-cov2_science.pdf660 KB
20200316_imperial_college_covid-19_response_team_report_9_-_impact_of_non-pharmaceutical_interventions_npis_to_reduce_covid-19_mortality_and_healthcare_demand.pdf1018 KB
20200316_science_-_disease_experts_call_for_nationwide_closure_of_u.s._schools_and_businesses_to_slow_coronavirus_science_aaas.pdf849 KB
20200317_nature-_the_proximal_origin_of_sars-cov-2_nature_medicine.pdf306 KB
20200317_scripps_research_-_the_covid-19_coronavirus_epidemic_has_a_natural_origin_scientists_say_scripps_research.pdf1.03 MB
20200317_science_-_coronavirus_cases_have_dropped_sharply_in_south_korea._whats_the_secret_to_its_success_science_aaas.pdf1.38 MB
20200317_nejm_-_epidemiology_of_covid-19_in_a_long-term_care_facility_in_king_county_washington_nejm.pdf588 KB
20200317_jama_-_coronavirus_disease_2019_covid-19_in_italy_critical_care_medicine_jama_jama_network.pdf360 KB
20200317_nejm_-_aerosol_and_surface_stability_of_sars-cov-2_as_compared_with_sars-cov-1_nejm.pdf466 KB
20200318_nature_-_coronavirus_vaccines_-_five_key_questions_as_trials_begin.pdf191 KB
20200318_nejm_-a_trial_of_lopinavir-ritonavir_in_adults_hospitalized_with_severe_covid-19_nejm.pdf794 KB
20200318_nejm_-_sars-cov-2_infection_in_children_nejm.pdf450 KB
20200319_ap_-_china_exonerates_doctor_reprimanded_for_warning_of_virus_01.pdf557 KB
20200319_nature_-_estimating_clinical_severity_of_covid-19_from_the_transmission_dynamics_in_wuhan_china_nature_medicine.pdf534 KB
20200320_biorxiv_npr_preprint_-_an_orally_bioavailable_broad-spectrum_antiviral_inhibits_sars-cov-2_and_multiple_endemic_epidemic_and_bat_coronavirus_biorxiv.pdf294 KB
20200320_international_journal_of_antimicrobial_agents_via_science_direct_-_hydroxychloroquine_and_azithromycin_as_a_treatment_of_covid-19_results_of_an_open-label_non-randomized_clinical_trial_-_sciencedirect_see_contrary_statements.pdf342 KB
20200401_lancet_-_feasibility_of_controlling_covid-19_outbreaks_by_isolation_of_cases_and_contacts_-_the_lancet_global_health.pdf421 KB
20200407_promed_-_coronavirus_disease_2019_update_88_germany_animals_research_pig_chicken_bat_ferret_.pdf113 KB
20200410_stat_-_covid-19_immunity_certificates_practical_and_ethical_conundrums_-_stat.pdf126 KB
20200410_medrxiv_npr_preprint_-_efficacy_of_hydroxychloroquine_in_patients_with_covid-19_results_of_a_randomized_clinical_trial_medrxiv.pdf220 KB
20200413_cdc_mmwr_-_timing_of_community_mitigation_and_changes_in_reported_covid-19_and_community_mobility_-_four_u.s._metropolitan_areas_february_26-april_1_2020_mmwr.pdf430 KB
20200414_harvard_crimson_-_as_coronavirus_spreads_false_theories_linking_harvard_professor_lieber_to_diseases_origin_proliferate_online_news_the_harvard_crimson.pdf1.24 MB
20200414_science_-_projecting_the_transmission_dynamics_of_sars-cov-2_through_the_postpandemic_period_science.pdf782 KB
20200414_harvard_gazette_-_warm_weather_may_have_no_impact_on_covid-19_-_harvard_gazette.pdf4.2 MB
20200414_ap_-_china_didnt_warn_public_of_likely_pandemic_for_6_key_days.pdf1.22 MB
20200414_wapo_-_state_department_cables_warned_of_safety_issues_at_wuhan_lab_studying_bat_coronaviruses_-_the_washington_post.pdf118 KB
20200415_nature_-_china_is_tightening_its_grip_on_coronavirus_research.pdf232 KB
20200415_cbs_boston_-_cdc_reviewing_stunning_universal_testing_results_from_boston_homeless_shelter.pdf40 KB
20200416_ap_-_chinas_virus_death_toll_revised_up_sharply_after_review.pdf235 KB
20200416_reuters_-_coronavirus_clue_most_cases_aboard_u.s._aircraft_carrier_are_symptom-free_-_reuters.pdf31 KB
20200416_medrxiv_npr_preprint_-_a_serological_assay_to_detect_sars-cov-2_seroconversion_in_humans_medrxiv.pdf161 KB
20200416_cyberscoop_-_coronavirus_scientists_are_big_targets_for_foreign_cyber-espionage_fbi_says.pdf36 KB
20200417_johns_hopkins_biosecurity_-_global_progress_on_covid-19_serology-based_testing.pdf184 KB
20200417_xinhua_-full_text_of_wuhans_notification_on_revising_numbers_of_confirmed_covid-19_cases_deaths_-_china.org_.cn_.pdf184 KB
20200417_science_-_how_does_coronavirus_kill_clinicians_trace_a_ferocious_rampage_through_the_body_from_brain_to_toes_science_aaas.pdf7.26 MB
20200420_contagion_-_discovering_covid-19_countermeasures_without_discarding_scientific_method.pdf641 KB
20200420_journal_of_biomolecular_structure_and_dynamics_-_novel_2019_coronavirus_structure_mechanism_of_action_antiviral_drug_promises_and_rule_out_against_its_treatment.pdf395 KB
20200421_county_of_santa_clara_public_health_-_county_of_santa_clara_identifies_three_additional_early_covid-19_deaths_-_novel_coronavirus_covid-19_-_county_of_santa_clara.pdf186 KB
20200421_medrxiv_npr_-_outcomes_of_hydroxychloroquine_usage_in_united_states_veterans_hospitalized_with_covid-19_medrxiv.pdf332 KB
20200505_infection_genetics_evolution._emergence_of_genomic_diversity_and_recurrent_mutations_in_sars-cov-2_.pdf728 KB
20200506_the_economist_-_covid-19_-_scientific_research_on_the_coronavirus_is_being_released_in_a_torrent_science_technology_the_economist.pdf1.07 MB
20200521_harvard_-_weather_conditions_and_covid-19_transmission-_estimates_and_projections.pdf2.53 MB
20200522_cdc_-_how_coronavirus_spreads_pdf.pdf75 KB
20200522_lancet_-_hydroxychloroquine_or_chloroquine_with_or_without_a_macrolide_for_treatment_of_covid-19_a_multinational_registry_analysis_-_the_lancet.pdf355 KB
rpp_20141208_nature_-_gain-of-function_experiments_time_for_a_real_debate_nature_reviews_microbiology.pdf332 KB
rpp_20151112_nature_-_engineered_bat_virus_stirs_debate_over_risky_research_nature_news_comment.pdf113 KB
rpp_20180912_emerg_microbes_infect_-_genomic_characterization_and_infectivity_of_a_novel_sars-like_coronavirus_in_chinese_bats.pdf1.07 MB
rpp_20181004_plos_pathogens_-_inoculating_science_against_potential_pandemics_and_information_hazards.pdf272 KB
rpp_20190710_iop_science_biofabrication_-_multi-cellular_engineered_living_systems_building_a_community_around_responsible_research_on_emergence_-_iopscience.pdf335 KB
rpp_20191019_jhu_wef_bmgf_-_event_201_public-private_cooperation_for_pandemic_preparedness.pdf201 KB